BTK and myeloid sarcoma: These findings suggest that BTK is involved in the chronic activation of monocytes and microglia in mice and humans, indicating that therapeutic inhibition of BTK may be desirable to control disease-driving activation of monocytes/macrophages and microglia in various forms of MS, including progressive disease.